Therafirst Medical Center

Recombinant Human Growth Hormone in Patients with HIV-Associated Wasting

Morris Schambelan, Kathleen Mulligan, Carl Grünfeld et al. · Annals of Internal Medicine · 1996 · 324 citations

Circulating hematopoietic stem and progenitor cells are myeloid-biased in cancer patients

Wenchao Wu, Hong-Wei Sun, Haitian Chen et al. · Proceedings of the National Academy of Sciences · 2014 · 211 citations · Full text

Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study

Jean‐Michel Molina, Anthony LaMarca, Jaime Andrade‐Villanueva et al. · The Lancet Infectious Diseases · 2011 · 171 citations

Daily Elvitegravir, Treatment And Prevention, Antiviral Drug Development +9

Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons

Colleen F. Kelley, Maribel Acevedo-Quiñones, Allison L. Agwu et al. · New England Journal of Medicine · 2024 · 169 citations

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study

Chloe Orkin, Edwin DeJesus, Moti Ramgopal et al. · The Lancet HIV · 2017 · 75 citations

Phase 3B, Treatment And Prevention, Medicine +9